Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279992 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
A Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02279992 is a Early Phase 1 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT02279992, a Early Phase 1 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant gliomas or metastatic brain cancer. This study will also determine the toxicity and tolerability of a phosphodiesterase-V inhibitor (vardenafil) in combination with intravenous carboplatin for patients with recurrent malignant gliomas or metastatic brain cancer.
Interventions
- DRUG Carboplatin
- DRUG Vardenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-03-27 |
| Est. Completion | 2016-02-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02279992
The ClinicalTrials.gov registry entry for NCT02279992 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT02279992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02279992 about?
NCT02279992 is a clinical study titled "Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases". This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant gliomas or metastatic brain cancer. This study will also determine the t...
What is the current status of trial NCT02279992?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2012-03-27. Estimated completion is 2016-02-11.
What interventions are being tested in trial NCT02279992?
The interventions under investigation include: Carboplatin (DRUG), Vardenafil (DRUG).
Who is sponsoring clinical trial NCT02279992?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.